David W Crabb Net Worth

The estimated Net Worth of David W Crabb is at least $186 Tisíc dollars as of 17 August 2012. David Crabb owns over 10,000 units of Basis Global Technologies Inc stock worth over $185,772 and over the last 21 years David sold BASI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Crabb BASI stock SEC Form 4 insiders trading

David has made over 2 trades of the Basis Global Technologies Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently David bought 10,000 units of BASI stock worth $12,600 on 17 August 2012.

The largest trade David's ever made was buying 10,000 units of Basis Global Technologies Inc stock on 17 August 2012 worth over $12,600. On average, David trades about 3,767 units every 302 days since 2004. As of 17 August 2012 David still owns at least 11,300 units of Basis Global Technologies Inc stock.

You can see the complete history of David Crabb stock trades at the bottom of the page.

What's David Crabb's mailing address?

David's mailing address filed with the SEC is 4344 NORTH PENNSYLVANIA ST, , INDIANAPOLIS, IN, 46205.

Insiders trading at Basis Global Technologies Inc

Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure a William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.

What does Basis Global Technologies Inc do?

Complete history of David Crabb stock trades at Basis Global Technologies Inc

Basis Global Technologies Inc executives and stock owners

Basis Global Technologies Inc executives and other stock owners filed with the SEC include:

• Wendy Perrow,
  Independent Director
• R. Matthew Neff,
  Independent Director
• Richard Johnson,
  Independent Director
• Joseph Flynn,
  Chief Commercial Officer
• John Sagartz,
  Chief Strategy Officer, Director
• Connie Dougherty,
  Vice President - Business Development
• I.M. Grossi,
  Vice President - Toxicology
• Philip Downing,
  Vice President - Preclinical Services
• Andrew Alexander,
  Vice President - Pharmacology and Toxicology Operations
• Michael Baim,
  Vice President - Bioanalytical Operations
• Beth Taylor,
  Chief Financial Officer, Vice President - Finance
• Robert Leasure,
  President, Chief Executive Officer, Director
• Gregory Davis,
  Interim Chairman of the Board
• Jill Blumhoff,
  VP, Finance & CFO
• John P Devine,
  VP--Toxicology
• James Sevall Bourdage,
  VP, Bioanalytical Services
• Jacqueline M Lemke,
  CFO & Vice President--Finance
• Jeffrey Potrzebowski,
  VP, Finance & CFO
• John Gregory Beattie,
  Chief Operating Officer
• Peterkissinger Candice B Ki...,
  
• Daniel Thomas Oakley,
  Chief Operating Officer
• Kimberly L Sagartz,
  10% owner
• Chrysalis, Llc Sw,
  10% owner
• Lori Payne,
  VP Bioanalytical Services
• Larry Steven Boulet,
  Director
• David W Crabb,
  Director
• John B. Landis,
  Director
• David L Omachinski,
  Director
• Anthony S Chilton,
  COO, Scientific Studies
• A. Charlene Sullivan,
  Director
• Alberto F Jr Hidalgo,
  VP, Bus. Development & Mrkting
• Leslie B Daniels,
  Director
• Kathleen Hodges,
  Vice President of Quality
• Lina L Reeves Kerner,
  V.P. - Human Resources
• Richard M Shepperd,
  President & Chief Exec. Off.
• Ronald E Shoup,
  Chief Operating Officer
• Craig S Bruntlett,
  Sr. V.P. International Sales
• Jon Brewer,
  VP Sales/Marketing
• William E Baitinger,
  Director
• Candice B Kissinger,
  Vice President
• Margaret B Mcclure,
  Dir, Pharmaceutical Lab. Div.
• Michael R Cox,
  V.P. Finance, CFO
• Emilio Cordova,
  V.P. of Business Development
• Edward Chait,
  Executive Vice President
• Gerry Henningsen,
  Director BAS Evansville
• Donnie A Evans,
  Vice President Engineering
• Garyl W Doster,
  Director
• Michael P Silvon,
  Vice President
• Michael S Noone,
  Dir. of Clinical Affairs, Balt
• William Sawyers,
  Laboratory Director
• William D Pitchford,
  Chief HR Officer